Strides Pharma Science Limited
NSE: STAR BSE: STAR
NSE
640.75
-12.25 (-1.88%)
Prev Close
653
Open Price
653
Volume
243,236
Today Low / High
639 / 664.95
52 WK Low / High
513.05 / 1675
Range
609 - 673
BSE
642.05
-10.70 (-1.64%)
Prev Close
652.75
Open Price
665.85
Volume
13,974
Today Low / High
639 / 665.85
52 WK Low / High
530.7 / 1675.25
Range
610 - 674
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 640.75 (target range: 609 - 673), reflecting a change of -12.25 (-1.87596%). On the BSE, it is listed at 642.05 (target range: 610 - 674), showing a change of -10.7 (-1.63922%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
21 Apr
653.00
-1.88%
17 Apr
660.00
-1.06%
16 Apr
624.90
6.43%
15 Apr
616.50
0.47%
11 Apr
616.00
-0.11%
09 Apr
594.80
-1.75%
08 Apr
603.15
-1.43%
07 Apr
513.05
12.23%
04 Apr
699.15
-10.87%
03 Apr
670.00
4.35%
02 Apr
667.00
0.38%
01 Apr
674.75
-1.19%
28 Mar
656.00
2.01%
27 Mar
670.00
-2.21%
26 Mar
692.00
-1.42%
25 Mar
727.10
-4.62%
24 Mar
704.05
3.12%
Strides Pharma Science Limited Graph
Strides Pharma Science Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Strides Pharma Science Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 640.75, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 642.05 | 648.47 | 583.62 - 713.32 |
| 654.89 | 523.91 - 785.87 | ||
| 661.31 | 462.92 - 859.70 | ||
| Bearish Scenario | 642.05 | 635.63 | 572.07 - 699.19 |
| 629.21 | 503.37 - 755.05 | ||
| 622.79 | 435.95 - 809.63 |
Overview of Strides Pharma Science Limited
ISIN
INE939A01011
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
712,606
Market Cap
59,053,256,433
Last Dividend
2.5
Official Website
IPO Date
2002-06-26
DCF Diff
654.46
DCF
-7
Financial Ratios Every Investor Needs
Stock Dividend of STAR
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-09 | September 09, 24 | 2.5 | 2.5 | 2024-09-09 | 2024-10-25 | |
| 2023-08-04 | August 04, 23 | 1.5 | 1.5 | 2023-08-04 | 2023-09-27 | |
| 2021-08-05 | August 05, 21 | 2.5 | 2.5 | 2021-08-06 | 2021-10-03 | |
| 2020-07-24 | July 24, 20 | 2 | 2 | 2020-07-27 | 2020-09-19 | |
| 2019-08-22 | August 22, 19 | 12 | 12 | 2019-08-23 | 2019-08-27 | 2019-07-29 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3,891.02 Cr | 1,725.18 Cr | 2,165.84 Cr | 0.5566 | 0.00 Cr | 155.99 Cr | 522.58 Cr | -70.61 Cr | -7.76 | 376.47 Cr | -0.0181 |
| 2023-03-31 | 3,688.39 Cr | 1,626.89 Cr | 2,061.50 Cr | 0.5589 | 63.87 Cr | 147.68 Cr | -79.70 Cr | -230.90 Cr | -25.63 | 502.73 Cr | -0.0626 |
| 2022-03-31 | 3,022.06 Cr | 1,583.28 Cr | 1,438.77 Cr | 0.4761 | 89.39 Cr | 151.21 Cr | -282.43 Cr | -474.25 Cr | -52.84 | -134.56 Cr | -0.1569 |
| 2021-03-31 | 3,251.16 Cr | 1,408.78 Cr | 1,842.38 Cr | 0.5667 | 105.91 Cr | 115.13 Cr | 456.92 Cr | 268.44 Cr | 28.40 | 725.04 Cr | 0.0826 |
| 2020-03-31 | 2,656.75 Cr | 1,183.98 Cr | 1,472.76 Cr | 0.5543 | 103.97 Cr | 115.10 Cr | 208.16 Cr | 36.39 Cr | 2.70 | 486.41 Cr | 0.0137 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 161.02 Cr | 5,839.76 Cr | 3,768.05 Cr | 2,125.5630 Cr | 2,516.87 Cr | 2,355.85 Cr | 1,126.24 Cr | 977.30 Cr | 26.04 Cr | 0.00 Cr | 72.97 Cr | 2,879.2590 Cr |
| 2023-03-31 | 303.50 Cr | 6,638.42 Cr | 4,465.54 Cr | 2,212.2580 Cr | 3,029.57 Cr | 2,726.07 Cr | 1,146.51 Cr | 1,372.55 Cr | 32.45 Cr | 0.00 Cr | 324.74 Cr | 2,990.2010 Cr |
| 2022-03-31 | 170.73 Cr | 6,975.86 Cr | 4,592.55 Cr | 2,359.2280 Cr | 3,025.03 Cr | 2,854.30 Cr | 1,173.80 Cr | 1,513.64 Cr | 28.12 Cr | 0.00 Cr | -22.73 Cr | 3,411.6750 Cr |
| 2021-03-31 | 125.83 Cr | 7,015.02 Cr | 4,201.02 Cr | 2,776.6610 Cr | 2,348.23 Cr | 2,222.39 Cr | 1,200.70 Cr | 1,499.45 Cr | 239.96 Cr | 323.37 Cr | 462.94 Cr | 2,738.3480 Cr |
| 2020-03-31 | 182.23 Cr | 6,151.73 Cr | 3,557.08 Cr | 2,527.4170 Cr | 2,234.66 Cr | 2,052.43 Cr | 782.54 Cr | 1,463.94 Cr | 362.97 Cr | 133.33 Cr | 268.00 Cr | 2,544.8570 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 701.0650 Cr | -150.2500 Cr | -693.3230 Cr | 582.9140 Cr | -142.4810 Cr | 161.0200 Cr | -118.1510 Cr | -62.7240 Cr | -384.4560 Cr | -13.5170 Cr | 30.7040 Cr |
| 2023-03-31 | 44.4110 Cr | 302.4740 Cr | -213.9210 Cr | -50.5270 Cr | 132.7710 Cr | 303.5010 Cr | -94.9380 Cr | -267.6310 Cr | 24.9280 Cr | 0.0000 Cr | -8.1380 Cr |
| 2022-03-31 | -257.8150 Cr | -118.7330 Cr | 421.3160 Cr | -401.1980 Cr | 44.8960 Cr | 170.7300 Cr | -143.3830 Cr | -652.5130 Cr | 137.4920 Cr | -22.4310 Cr | 28.1860 Cr |
| 2021-03-31 | 481.4370 Cr | -520.8210 Cr | -15.7960 Cr | 183.9530 Cr | -56.4000 Cr | 125.8340 Cr | -297.4840 Cr | 289.3800 Cr | 174.9380 Cr | -17.9150 Cr | -414.0490 Cr |
| 2020-03-31 | 204.7870 Cr | 1,306.1590 Cr | -1,709.4490 Cr | 54.7850 Cr | -183.6550 Cr | 182.2340 Cr | -150.0020 Cr | 48.5080 Cr | -1,349.6130 Cr | -153.8950 Cr | -162.5240 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 1,153.67 Cr | 480.12 Cr | 673.54 Cr | 0.5838 | 161.89 Cr | 87.95 Cr | 9.56 | 214.45 Cr | 0.0762 |
| 2024-09-30 | 1,201.11 Cr | 767.86 Cr | 433.25 Cr | 0.3607 | 185.28 Cr | 93.23 Cr | 10.14 | 247.54 Cr | 0.0776 |
| 2024-06-30 | 1,087.51 Cr | 681.21 Cr | 406.30 Cr | 0.3736 | 168.39 Cr | 70.20 Cr | 7.64 | 225.96 Cr | 0.0646 |
| 2024-03-31 | 1,084.04 Cr | 665.15 Cr | 418.88 Cr | 0.3864 | 179.97 Cr | 18.18 Cr | 1.98 | 208.12 Cr | 0.0168 |
| 2023-12-31 | 1,037.67 Cr | 421.24 Cr | 616.43 Cr | 0.5940 | 107.49 Cr | 49.67 Cr | -0.49 | 192.50 Cr | 0.0479 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 130.64 Cr | 204.48 Cr | 335.12 Cr | 0.00 Cr | 1,210.60 Cr | 3,094.02 Cr | 998.77 Cr | 5,989.63 Cr | 3,774.63 Cr |
| 2024-06-30 | -296.92 Cr | 593.85 Cr | 296.92 Cr | 0.00 Cr | 0.00 Cr | 296.92 Cr | 0.00 Cr | 0.00 Cr | -2,071.71 Cr |
| 2024-03-31 | 191.17 Cr | 105.76 Cr | 296.92 Cr | 1,141.87 Cr | 1,126.24 Cr | 2,969.00 Cr | 958.55 Cr | 5,839.76 Cr | 3,768.05 Cr |
| 2023-12-31 | -326.31 Cr | 652.62 Cr | 326.31 Cr | 0.00 Cr | 0.00 Cr | 326.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 98.87 Cr | 334.11 Cr | 432.98 Cr | 0.00 Cr | 1,137.63 Cr | 3,389.21 Cr | 972.52 Cr | 6,337.80 Cr | 4,344.29 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 70.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 18.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 49.67 Cr | 102.46 Cr | 0.00 Cr | 0.00 Cr | 102.46 Cr | 365.64 Cr | 263.19 Cr | 0.00 Cr | 102.46 Cr |
| 2023-09-30 | -131.34 Cr | 120.21 Cr | 0.00 Cr | 0.00 Cr | 120.21 Cr | 263.19 Cr | 142.98 Cr | 0.00 Cr | 120.21 Cr |
| 2023-06-30 | -7.11 Cr | 119.18 Cr | 0.00 Cr | 0.00 Cr | 119.18 Cr | 428.78 Cr | 309.60 Cr | 0.00 Cr | 119.18 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,619,911,900.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
MD & Group Chief Executive Officer
Mr. Badree Komandur
Gender: male
Year Born: 1972
Chief Operating Officer
Mr. P. V. S. Ramaraju
Gender: male
Year Born:
Executive Vice President of Operations
Mr. C. K. Sundar
Gender: male
Year Born:
Senior Vice President of Strides Pharma Inc.
Mr. Kevin P. Cook
Gender: male
Year Born:
Founder & Non-Executive Chairperson
Mr. Arun Kumar Pillai B.Com.
Gender: male
Year Born: 1961
Executive Director of Business Development & Director
Mr. Aditya Arun Kumar
Gender: male
Year Born:
Group General Counsel, Chief Risk Officer & Chief Sustainability Officer
Sormistha Ghosh
Gender: Not Specified
Year Born:
Group Chief Human Resource Officer
Ms. Surabhi Loshali
Gender: female
Year Born: 1980
Compliance Officer & Company Secretary
Ms. Manjula Ramamurthy
Gender: female
Year Born:
Group Chief Financial Officer & Chief Investor Relations Officer
Mr. Vikesh Kumar
Gender: male
Year Born: 1985
FAQs about Strides Pharma Science Limited
Who is the CEO of the company?
The CEO is Mr. Badree Komandur.
What is the current market price of the stock?
The current price is ₹640.75.
What is the 52-week price range?
The range is ₹513.05-1675.
What is the market capitalization of the company?
The market capitalization is ₹5,905.33 crores.
What is the dividend yield?
The dividend yield is 0.39%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 21.87.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Strides Pharma Science Limited (ISIN: INE939A01011) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹5,905.33 crores and an average daily volume of 712,606 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.5.